ESCAPE-NA1 Trial Brings Hope of Neuroprotective Drugs for Acute Ischemic Stroke: Highlights of the Phase 3 Clinical Trial on Nerinetide

Stroke is a leading disease for morbidity and the second leading cause of mortality following ischemic heart disease. The health burden for stroke ranks the fourth of all diseases as measured in disability-adjusted life years[1]. Worldwide annual new stroke incidence is approximately 16 million with the increasing trend of an epidemic due to the aging population [2].